Evidence map›Paper›PMID 36093297›Full record

ArticleOncotarget2022

Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.

Francis R LeBlanc, Zainul S Hasanali, August Stuart, Sara Shimko, Kamal Sharma, Violetta V Leshchenko, Samir Parekh, Haiqing Fu, Ya Zhang, Melvenia M Martin and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Francis R LeBlancDepartment of Medicine, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.
Zainul S HasanaliDepartment of Medicine, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.
August StuartDepartment of Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.
Sara ShimkoDepartment of Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.
Kamal SharmaBayCare Medical Group, Cassidy Cancer Center, Winter Haven, FL 33881, USA.
Violetta V LeshchenkoDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Samir ParekhDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Haiqing FuDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Ya ZhangDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Melvenia M MartinDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Mark KesterDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Todd FoxDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Jiangang LiaoDepartment of Public Health Sciences, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Thomas P LoughranDepartment of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, VA 22908, USA.
Juanita EvansDepartment of Anatomic Pathology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Jeffrey J PuDepartment of Medicine and Cancer Center, University of Arizona College of Medicine, Tucson, AZ 85724, USA.
Stephen E SpurgeonDepartment of Medicine, Oregon Health and Science University, Portland, OR 97239, USA.
Mirit I AladjemDevelopmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Elliot M EpnerBeverly Hills Cancer Center, Beverly Hills, CA 90211, USA.
Center for Cancer Research · USPenn State Milton S. Hershey Medical Center · USIcahn School of Medicine at Mount Sinai · USPennsylvania State University · USUniversity of Virginia · USBeverly Hills Cancer Center · USHealth First · USOregon Health & Science University · USUniversity of Arizona · USUniversity of Virginia Cancer Center

Funding

Initiation of DNA Replication in Mammalian CellsZIABC010411 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALADJEM, MIRIT · 2009 to 2025
$25.0M
HEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAMT32HL007439 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE F BRASS, PETER S KLEIN · 1985 to 2026
$17.1M
Paul Calabresis Career Development Award For Clinical Oncology K12CA132783 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PEREZ-SOLER, ROMAN, VERMA, AMIT K. · 2009 to 2019
$8.2M
Survival Mechanisms in Leukemic NK CellsR01CA098472 · NCI · UNIVERSITY OF VIRGINIA · PI LOUGHRAN, THOMAS P. · 2003 to 2016
$4.0M
Intramural NIH HHS ZIA BC010411NCI NIH HHS K12 CA132783NCI NIH HHS R01 CA098472NHLBI NIH HHS T32 HL007439
6 · The paper itself

Abstract

Classical MCL (cMCL) constitutes 6-8% of all B cell NHL. Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer subtype of cMCL associated with an aggressive clinical course and poor treatment response, frequent relapse and poor outcomes. We treated 13 bMCL patients with combined epigenetic and immunotherapy treatment consisting of vorinostat, cladribine and rituximab (SCR). We report an increased OS greater than 40 months with several patients maintaining durable remissions without relapse for longer than 5 years. This is remarkably better then current treatment regimens which in bMCL range from 14.5-24 months with conventional chemotherapy regimens. We demonstrate that the G/A870

Indexed as

Epigenesis, GeneticImmunotherapyLymphoma, Mantle-CellAdultAntigens, CD20CladribineHumansImmunologic FactorsNeoplasm Recurrence, LocalRituximabVorinostatAntigens, CD20CladribineImmunologic FactorsRituximabVorinostatblastic mantle cell lymphomacladribineepigenetics

Identifiers

PMID36093297
PMCPMC9450988
OpenAlexW4292186328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.